Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis.

ABSTRACT:

Introduction

Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant T_H2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been approved for the treatment of adult patients with moderate-to-severe AD whose current treatment options are limited.

Aim

This article reviews the evidence of clinical efficacy, safety, and patient-reported out-come (PRO) measures from Phase I-III trials of dupilumab in adult patients with moderate-to-severe AD.

Evidence review

Results from clinical trials of dupilumab in adults with moderate-to-severe AD have shown that weekly or biweekly dupilumab injections significa

SUBMITTER: Eshtiaghi P 

PROVIDER: S-EPMC5826246 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature